D-Cycloserine to Enhance Extinction to Alcohol Cues

This study has been completed.
Boston University
Brown University
Information provided by (Responsible Party):
University of Georgia
ClinicalTrials.gov Identifier:
First received: May 24, 2011
Last updated: February 14, 2014
Last verified: May 2011

There is considerable evidence that Alcohol Use Disorders (AUDs) can be understood as a form of dysregulated learning and are influenced by classical conditioning. This is based on numerous studies indicating that conditioned contextual cues influence craving for alcohol consumption. As a result, there has been considerable interest in extinction-based treatments for AUDs (i.e., treatments that focus on extinguishing the associations between alcohol cues and motivation to drink), referred to as cue exposure treatment To date, extinction-based treatment for AUDs has resulted in disappointing outcomes in clinical trials and there is considerable interest in improving this form of treatment. One novel strategy is the use of pharmacological adjuncts to enhance extinction. Medications that maximize extinction may minimize subsequent reactions to alcohol cues and, in turn, subsequent clinical outcomes. This study is examining whether the medication d-cycloserine (DCS) can enhance extinction to alcohol cues. Recent basic research has revealed that DCS enhances extinction to fear cues and several lines of evidence suggest that DCS may also enhance extinction to alcohol cues. Therefore, DCS may serve as a useful pharmacological adjunct to extinction-based treatment for AUDs. Our primary aim is to examine whether, compared to placebo, DCS (50 mg) will enhance extinction to alcohol cues under controlled laboratory conditions in treatment-seeking individuals with alcohol use disorders. We hypothesize that DCS will generate greater extinction compared to placebo during the subsequent extinction session as measured by attenuated craving in response to alcohol cues. Furthermore, we hypothesize that DCS will generate greater extinction compared to placebo at follow-up assessments. This study is a proof-of-concept test of whether DCS can reduce reactions to alcohol cues under controlled laboratory conditions. It is a preliminary study using a subclinical number of extinction sessions and medication administrations to establish whether or not DCS improves extinction in the laboratory. If proof-of-concept is supported, it will suggest that a clinical trial is warranted. A clinical sample and clinical context are used to maximize the potential generalizability from this exploratory study.

Condition Intervention
Alcohol Use Disorders.
Drug: d-cycloserine.

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: D-Cycloserine to Enhance Extinction to Alcohol Cues

Resource links provided by NLM:

Further study details as provided by University of Georgia:

Primary Outcome Measures:
  • Change in Craving for alcohol. [ Time Frame: Laboratory sessions (two, one-week apart): change in craving over 11 occasions, 5 minutes apart. Between sessions: change in craving across 7 occasions (Study Day: 1, 4, 7, 12, 19, 33, 40). ] [ Designated as safety issue: No ]
    Subjective desire for alcohol is assessed intermittently during extended exposure to alcohol cues with response prevention within laboratory sessions and over the preceding week at 6 study visits.

Secondary Outcome Measures:
  • Change in Tolerability [ Time Frame: Prevalence and change in side effects measured on 4 occasions (Study Day: 1, 4, 7, 12) ] [ Designated as safety issue: Yes ]
    Side effects resulting from d-cycloserine in individuals with alcohol use disorders.

Enrollment: 37
Study Start Date: November 2010
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Inert filler in matched pill.
Drug: d-cycloserine.
50 mg administered on two occasions.
Other Name: Seromycin.
Active Comparator: d-cycloserine 50 mg
50 mg d-cycloserine.
Drug: d-cycloserine.
50 mg administered on two occasions.
Other Name: Seromycin.


Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Presence of an alcohol use disorder.
  2. At least 14+/7+ drinks/week for males/females.
  3. Alcohol cue reactivity.
  4. 9th grade education or greater.
  5. 21-65 years old.
  6. Stable contact information.
  7. Treatment-seeking.

Exclusion Criteria:

  1. Participation in a previous study of d-cycloserine.
  2. Mandated to treatment.
  3. Significant withdrawal symptoms (i.e., Clinical Institute Withdrawal Scale - Revised score of 15+, history of previous withdrawal-related hospitalizations, or withdrawal-related hallucinations).
  4. Current DSM IV Axis I conditions other than alcohol and nicotine dependence.
  5. Living with a previous study participant.
  6. No medical contraindications for d-cycloserine (i.e., currently taking ethionamide, isoniazid, SSRIs, history of epilepsy, history of hypersensitivity to DCS, or additional medical conditions deemed a risk at the physical exam by a study physician).
  7. Cardiovascular disease or uncontrolled hypertension (such conditions may contribute to abnormal psychophysiological arousal data), as determined by the study physician.
  8. Pregnant or seeking to conceive (females only).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01362309

United States, Georgia
Experimental and Clinical Psychopharmacology Laboratory, Dept. of Psychology, University of Georgia
Athens, Georgia, United States, 30605
Sponsors and Collaborators
University of Georgia
Boston University
Brown University
Principal Investigator: James MacKillop, PhD University of Georgia
  More Information

No publications provided

Responsible Party: University of Georgia
ClinicalTrials.gov Identifier: NCT01362309     History of Changes
Other Study ID Numbers: R21 AA017696, R21AA017696
Study First Received: May 24, 2011
Last Updated: February 14, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Georgia:

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Antibiotics, Antitubercular
Antitubercular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Renal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 26, 2015